应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02595 劲方医药-B
未开盘 04-01 16:08:31
36.980
+3.560
+10.65%
最高
38.260
最低
33.000
成交量
606.09万
今开
33.000
昨收
33.420
日振幅
15.74%
总市值
136.83亿
流通市值
124.99亿
总股本
3.70亿
成交额
2.15亿
换手率
1.79%
流通股本
3.38亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
异动解读 | 劲方医药-B获Wellington Management增持,盘中大涨5.14%
异动解读 · 03-31 10:10
异动解读 | 劲方医药-B获Wellington Management增持,盘中大涨5.14%
Wellington Management Group LLP增持劲方医药-B(02595)约31.82万股 每股均价约30.88港元
智通财经 · 03-30 19:25
Wellington Management Group LLP增持劲方医药-B(02595)约31.82万股 每股均价约30.88港元
里昂:升劲方医药-B(02595)目标价至61.9港元 评级“跑赢大市”
智通财经 · 03-26
里昂:升劲方医药-B(02595)目标价至61.9港元 评级“跑赢大市”
异动解读 | 劲方医药-B盘中大涨5.34%,年度业绩增长及核心药物III期进展成催化剂
异动解读 · 03-25
异动解读 | 劲方医药-B盘中大涨5.34%,年度业绩增长及核心药物III期进展成催化剂
劲方医药-B(02595):黄美凤获委任为联席公司秘书
智通财经 · 03-25
劲方医药-B(02595):黄美凤获委任为联席公司秘书
劲方医药-B(02595)发布年度业绩 净亏损17.95亿元 同比扩大164.82%
智通财经 · 03-25
劲方医药-B(02595)发布年度业绩 净亏损17.95亿元 同比扩大164.82%
Wellington Management Group LLP增持劲方医药-B(02595)382.34万股 每股作价25.5港元
智通财经 · 03-23
Wellington Management Group LLP增持劲方医药-B(02595)382.34万股 每股作价25.5港元
劲方医药-B(02595)将于2026年AACR年会上展示三款RAS通路相关的大、小分子靶向药临床前研究数据
智通财经 · 03-20
劲方医药-B(02595)将于2026年AACR年会上展示三款RAS通路相关的大、小分子靶向药临床前研究数据
劲方医药(02595)午后涨22.54% 公司宣布三款新药入选AACR壁报环节
金吾财讯 · 03-20
劲方医药(02595)午后涨22.54% 公司宣布三款新药入选AACR壁报环节
劲方医药-B涨超15%
每日经济新闻 · 03-20
劲方医药-B涨超15%
Wellington Management Group LLP增持劲方医药-B(02595)252.42万股 每股作价约27.26港元
智通财经 · 03-19
Wellington Management Group LLP增持劲方医药-B(02595)252.42万股 每股作价约27.26港元
劲方医药-B盘中异动 早盘股价大跌5.09%报29.460港元
市场透视 · 03-13
劲方医药-B盘中异动 早盘股价大跌5.09%报29.460港元
劲方医药-B03月09日获主力加仓1300.8万元
市场透视 · 03-09
劲方医药-B03月09日获主力加仓1300.8万元
港股异动 | 劲方医药-B(02595)涨超11% 公司将获纳入港股通 预计GFH375治疗结果将于国际学术会议发布
智通财经 · 03-09
港股异动 | 劲方医药-B(02595)涨超11% 公司将获纳入港股通 预计GFH375治疗结果将于国际学术会议发布
劲方医药-B03月06日获主力加仓316.0万元
市场透视 · 03-06
劲方医药-B03月06日获主力加仓316.0万元
劲方医药-B(02595)2月无新增发行或股份变动
公告速递 · 03-05
劲方医药-B(02595)2月无新增发行或股份变动
每日卖空追踪 | 劲方医药-B 03月05日卖空量成交11.04万股,卖空比例为16.41%
市场透视 · 03-05
每日卖空追踪 | 劲方医药-B 03月05日卖空量成交11.04万股,卖空比例为16.41%
劲方医药-B盘中异动 早盘股价大跌5.03%
市场透视 · 03-04
劲方医药-B盘中异动 早盘股价大跌5.03%
每日卖空追踪 | 劲方医药-B 03月02日卖空量成交10.92万股,卖空比例为25.5%
市场透视 · 03-02
每日卖空追踪 | 劲方医药-B 03月02日卖空量成交10.92万股,卖空比例为25.5%
劲方医药-B(02595):GFH375获得国内首个KRAS G12D抑制剂治疗非小细胞肺癌的突破性疗法认定
智通财经 · 03-02
劲方医药-B(02595):GFH375获得国内首个KRAS G12D抑制剂治疗非小细胞肺癌的突破性疗法认定
加载更多
公司概况
公司名称:
劲方医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
劲方医药科技(上海)有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发,以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发,分子工艺路线和质量标准的研究,以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":36.98,"timestamp":1775030911006,"preClose":33.42,"halted":0,"volume":6060942,"delay":0,"changeRate":0.10652304009575089,"floatShares":338000000,"shares":370000000,"eps":-6.917051981439679,"marketStatus":"未开盘","change":3.56,"latestTime":"04-01 16:08:31","open":33,"high":38.26,"low":33,"amount":215250977,"amplitude":0.157391,"askPrice":36.98,"askSize":1800,"bidPrice":36.92,"bidSize":2600,"shortable":3,"etf":0,"ttmEps":-6.112531602708803,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775093400000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":33.42,"openAndCloseTimeList":[[1775007000000,1775016000000],[1775019600000,1775030400000]],"volumeRatio":1.757208770849137,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"1172889689","title":"异动解读 | 劲方医药-B获Wellington Management增持,盘中大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172889689","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172889689?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:10","pubTimestamp":1774923054,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨5.14%,引起了市场的广泛关注。消息面上,劲方医药-B获得Wellington Management Group LLP增持约31.82万股,总金额约为982.60万港元,增持后持股比例达到7.02%。机构投资者的增持行为通常被视为对公司前景的积极信号,增强了市场信心。Wellington Management Group LLP作为知名投资机构,其增持动作可能反映了对劲方医药-B长期价值的认可,从而推动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314171","title":"Wellington Management Group LLP增持劲方医药-B(02595)约31.82万股 每股均价约30.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314171","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623314171?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:25","pubTimestamp":1774869941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新数据显示,3月26日,Wellington Management Group LLP增持劲方医药-B(02595)31.8247万股,每股均价30.8754港元,总金额约为982.60万港元。增持后最新持股数目约为2374.17万股,持股比例为7.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","02595","BK1515","EWH","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873168","title":"里昂:升劲方医药-B(02595)目标价至61.9港元 评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873168?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:04","pubTimestamp":1774494280,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,里昂发布研报称,劲方医药-B(02595)去年收入人民币1.3亿元,同比增长24.42%;研发成本2.82亿元,同比减少15.01%;净亏损17.95亿元,同比扩大164.82%,均优于市场预期。G12D GFH375已进入胰脏癌注册试验阶段,而pan-RAS GFH276有望成为劲方医药的长期增长动力。GFH276的I期剂量递增试验中已观察到积极的安全性讯号。该行称,将公司今年和明年盈利预测上调4%及5.3%,其目标价由60.8港元上调至61.9港元,维持其评级为跑赢大市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","02595","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122554050","title":"异动解读 | 劲方医药-B盘中大涨5.34%,年度业绩增长及核心药物III期进展成催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1122554050","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122554050?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:01","pubTimestamp":1774404060,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大涨5.34%,引起了市场的广泛关注。消息面上,公司发布了截至2025年12月31日止年度的年度业绩。公司收入达到1.3亿元人民币,同比增长约24.5%,增长主要得益于与Verastem就核心候选药物GFH375达成的合作及对外授权安排。其核心产品GFH375作为全球首个进入III期注册性临床试验的口服KRAS G12D抑制剂,已获得美国食品药品监督管理局的快速通道资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622014592","title":"劲方医药-B(02595):黄美凤获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622014592","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622014592?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:52","pubTimestamp":1774396324,"startTime":"0","endTime":"0","summary":"智通财经APP讯,劲方医药-B(02595)发布公告,吴东澄因其专业事务重新安排及更深入参与客户业务及策略管理,已提呈辞任联席公司秘书、授权代表及法律程序文件代理人,自2026年3月24日起生效。黄美凤已获委任为联席公司秘书、授权代表及法律程序文件代理人,自2026年3月24日起生效。张巍将继续担任公司另一名联席公司秘书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","09939","BK1161","02595","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622145900","title":"劲方医药-B(02595)发布年度业绩 净亏损17.95亿元 同比扩大164.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622145900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622145900?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:50","pubTimestamp":1774396243,"startTime":"0","endTime":"0","summary":"智通财经APP讯,劲方医药-B 发布截至2025年12月31日止年度业绩,收入人民币1.3亿元,同比增长24.42%;研发成本2.82亿元,同比减少15.01%;净亏损17.95亿元,同比扩大164.82%。公司历年来达成多个国内外授权交易,营业收入保持稳健。2025年度营业收入超过1.3亿元人民币、同比增幅近25%。此外公司现金流储备充足,截至2025年底现金及银行结余超过20亿元人民币。同时本公司是唯一一家在上市时拥有已商业化的1类创新药并产生对外授权收入的上市规则第18A章上市公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","02595","BK1574","BK1161","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621932770","title":"Wellington Management Group LLP增持劲方医药-B(02595)382.34万股 每股作价25.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621932770","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621932770?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:07","pubTimestamp":1774264076,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新数据显示,3月19日,Wellington Management Group LLP增持劲方医药-B(02595)382.34万股,每股作价25.5港元,总金额为9749.67万港元。增持后最新持股数目约为2159.22万股,持股比例为6.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","159938","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620731689","title":"劲方医药-B(02595)将于2026年AACR年会上展示三款RAS通路相关的大、小分子靶向药临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2620731689","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620731689?lang=zh_cn&edition=full","pubTime":"2026-03-20 21:33","pubTimestamp":1774013615,"startTime":"0","endTime":"0","summary":"智通财经APP讯,劲方医药-B(02595)发布公告,公司将于2026年AACR年会壁报环节展示GFH276(非降解性分子胶)、GFS784(新型偶联药物,连接功能性抗体及机制协同性靶向药载荷)、GFH603(类分子胶共价变构激活剂)三款产品的临床前研究数据。公司RAS疗法矩阵聚焦多种选择性和泛RAS抑制剂,亦持续关注RAS通路重要共突变的潜在靶点;该矩阵包含多元分子形态、多机制RAS通路相关的大、小分子靶向药。届AACR年会将于2026年4月17日至22日在美国圣地亚哥举行,公司参会壁报将分别于4月19日和4月21日展示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK1161","02595","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620713202","title":"劲方医药(02595)午后涨22.54% 公司宣布三款新药入选AACR壁报环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2620713202","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620713202?lang=zh_cn&edition=full","pubTime":"2026-03-20 13:36","pubTimestamp":1773984997,"startTime":"0","endTime":"0","summary":"金吾财讯 | 劲方医药 午后大幅拉升,截至发稿,报31.86港元,涨22.54%,成交额1.49亿港元。消息面上,据劲方医药官微消息,公司宣布其管线中三款新药的临床前研究成果入选2026年美国癌症研究协会壁报环节,今年AACR年会将于2026年4月17日至22日在美国圣地亚哥举行。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","02595","159938","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620820997","title":"劲方医药-B涨超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620820997","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620820997?lang=zh_cn&edition=full","pubTime":"2026-03-20 11:11","pubTimestamp":1773976290,"startTime":"0","endTime":"0","summary":"每经AI快讯,3月20日,劲方医药(02595.HK)涨超15%,截至发稿,涨15.54%,报30.04港元,成交额5094.15万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603203678572081.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203678572081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159938","02595","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247374","title":"Wellington Management Group LLP增持劲方医药-B(02595)252.42万股 每股作价约27.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247374","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620247374?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:53","pubTimestamp":1773921202,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新数据显示,3月17日,Wellington Management Group LLP增持劲方医药-B(02595)252.42万股,每股作价27.259港元,总金额约为6880.72万港元。增持后最新持股数目约为1776.94万股,持股比例为5.26%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","02595","BK1574","BK1161","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619193164","title":"劲方医药-B盘中异动 早盘股价大跌5.09%报29.460港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619193164?lang=zh_cn&edition=full","pubTime":"2026-03-13 09:35","pubTimestamp":1773365717,"startTime":"0","endTime":"0","summary":"2026年03月13日早盘09时35分,劲方医药-B股票出现异动,股价快速下挫5.09%。截至发稿,该股报29.460港元/股,成交量2.32万股,换手率0.01%,振幅5.48%。资金方面,该股资金流入0港元,流出57.0132万港元。劲方医药-B股票所在的药品行业中,整体跌幅为0.08%。其相关个股中,海西新药、中智药业、四环医药涨幅较大,振幅较大的相关个股有联邦制药、长风药业、宝济药业-B,振幅分别为5.36%、3.92%、3.51%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031309351797b0493e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031309351797b0493e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","BK1574","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618623355","title":"劲方医药-B03月09日获主力加仓1300.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623355","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618623355?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:15","pubTimestamp":1773044108,"startTime":"0","endTime":"0","summary":"03月09日, 劲方医药-B股价涨20.80%,报收30.32元,成交金额1.8亿元,换手率1.87%,振幅24.70%,量比7.74。劲方医药-B今日主力资金净流入1300.8万元,连续7日净流入,上一交易日主力净流入316.0万元。该股近5个交易日上涨9.16%,主力资金累计净流入2129.6万元,其中3个交易日为股价下跌时净流入;近20日主力资金累计净流入2252.9万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161522a45ad28b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161522a45ad28b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1515","BK1574","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618180316","title":"港股异动 | 劲方医药-B(02595)涨超11% 公司将获纳入港股通 预计GFH375治疗结果将于国际学术会议发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2618180316","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618180316?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:57","pubTimestamp":1773021454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,劲方医药-B涨超11%,截至发稿,涨9.96%,报27.6港元,成交额4006.33万港元。近日,劲方医药-B公告称,公司GFH375获得国内首个KRAS G12D抑制剂治疗非小细胞肺癌的突破性疗法认定。值得关注的是,GFH375治疗KRAS G12D突变型实体瘤及NSCLC的初步研究数据,曾在2025年登陆美国临床肿瘤学会年会及世界肺癌大会的突破性研究摘要 和现场口头报告,GFH375治疗NSCLC患者的最新研究结果预计将在今年国际学术会议发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","VXUS","02595","BK1161","BK4588","VT","BK4585","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617765260","title":"劲方医药-B03月06日获主力加仓316.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617765260","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617765260?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784910,"startTime":"0","endTime":"0","summary":"03月06日, 劲方医药-B股价涨7.91%,报收25.10元,成交金额2674.4万元,换手率0.32%,振幅8.94%,量比1.11。劲方医药-B今日主力资金净流入316.0万元,连续6日净流入,上一交易日主力净流入47.5万元。该股近5个交易日下跌9.05%,主力资金累计净流入923.1万元;近20日主力资金累计净流入1045.3万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161521a6aa28e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161521a6aa28e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","BK1574","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130194745","title":"劲方医药-B(02595)2月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1130194745","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130194745?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:36","pubTimestamp":1772699803,"startTime":"0","endTime":"0","summary":"2026年3月5日,劲方医药科技(上海)股份有限公司披露截至2026年2月28日的证券变动月报表。公司本月无新增发行或股份变动,股本结构与上月相比保持稳定。公司注册及已发行股本仍为人民币37,036,663元,合计已发行338,029,020股H股及32,337,610股未上市股份,总计370,366,630股。公司表示将持续遵守相关监管规定,并确保信息披露的合规与透明。本次公告由公司联席公司秘书张巍签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617483105","title":"每日卖空追踪 | 劲方医药-B 03月05日卖空量成交11.04万股,卖空比例为16.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617483105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617483105?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699433,"startTime":"0","endTime":"0","summary":"劲方医药-B北京时间03月05日,跌1.02%,卖空量成交11.04万股,较上一交易日减少74.43%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163424a6a5d977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163424a6a5d977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","09939","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617091550","title":"劲方医药-B盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617091550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617091550?lang=zh_cn&edition=full","pubTime":"2026-03-04 10:12","pubTimestamp":1772590352,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘10时12分,劲方医药-B股票出现波动,股价快速下跌5.03%。截至发稿,该股报23.780港元/股,成交量16.54万股,换手率0.05%,振幅6.07%。劲方医药-B股票所在的药品行业中,整体跌幅为0.48%。其相关个股中,德琪医药-B、开拓药业-B、凯莱英涨幅较大,振幅较大的相关个股有德琪医药-B、凯莱英、宝济药业-B,振幅分别为9.72%、8.80%、6.67%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304101232a4490585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304101232a4490585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","02595","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616382238","title":"每日卖空追踪 | 劲方医药-B 03月02日卖空量成交10.92万股,卖空比例为25.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616382238","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616382238?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:30","pubTimestamp":1772440235,"startTime":"0","endTime":"0","summary":"劲方医药-B北京时间03月02日,跌1.17%,卖空量成交10.92万股,较上一交易日减少72.34%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163502a730c7dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163502a730c7dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","BK1161","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616877444","title":"劲方医药-B(02595):GFH375获得国内首个KRAS G12D抑制剂治疗非小细胞肺癌的突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616877444?lang=zh_cn&edition=full","pubTime":"2026-03-02 08:04","pubTimestamp":1772409867,"startTime":"0","endTime":"0","summary":"智通财经APP讯,劲方医药-B 公布,口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单,拟用于至少接受过一种系统性治疗的KRAS G12D突变型非小细胞肺癌患者。本次认定基于GFH375X1101研究中NSCLC患者的治疗结果,I/II期试验数据展现了GFH375单药治疗KRAS G12D突变型NSCLC的同类最佳疗效、且整体安全性╱耐受性可控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","159938","BK1574","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":0.1556},{"period":"1month","weight":0.3656},{"period":"3month","weight":0.5551},{"period":"6month","weight":-0.0958},{"period":"1year","weight":0.8136},{"period":"ytd","weight":0.5551}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.0294},{"period":"3month","weight":-0.0131},{"period":"6month","weight":-0.068},{"period":"1year","weight":0.0899},{"period":"ytd","weight":-0.0131}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技(上海)有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发,以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发,分子工艺路线和质量标准的研究,以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}